Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists
Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists
Organovo在肝臟會議上重點介紹了FXR314在MASH中的2期結果，顯示相比其他FXR激動劑，具有顯著的肝脂減少和改善的安全性概況。
Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists
Organovo在肝臟大會上重點介紹了FXR314在MASH的2期結果，顯示與其他FXR激動劑相比，具有顯著的降低肝脂和改善安全性的優勢
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間